Effects of SSRI exposure on hemorrhagic complications and outcome following thrombolysis in ischemic stroke

Abstract

Background

Selective serotonin reuptake inhibitors (SSRI) may interfere with platelet function, and pre-stroke SSRI treatment has been associated with increased hematoma volumes and mortality in hemorrhagic stroke patients. The effects of SSRI on the risk of hemorrhagic complications after thrombolysis in ischemic stroke patients are unclear.

Aims

To examine the effects of pre-stroke SSRI exposure on bleeding complications, functional outcome, and mortality following thrombolysis in ischemic stroke.

Methods

Data including standard demographic and clinical variables as well as baseline and follow-up stroke severity (measured by National Institutes of Health Stroke Score), functional outcome (measured by modified Rankin Scale) at 3 months, and mortality at 7 and 90 days were extracted from the Virtual International Stroke Trials Archive. Multivariable binary logistic regression was used for statistical analyses.

Results

Out of 1114 ischemic stroke patients treated with recombinant tissue-type plasminogen activator, 135 (12.1%) had previous SSRI exposure. Symptomatic intracranial hemorrhage occurred in 30 (2.7%) patients. Of those, 2 (1.5%, n = 135) were in the SSRI pretreatment group and 28 (2.9%, n = 979) were SSRI naive patients. Pre-stroke SSRI exposure in thrombolysed patients showed association with neither bleeding complications (P = .58) nor functional outcome (P = .38) nor mortality (P = .65).

Conclusions

Results from this large retrospective ad hoc database cohort study indicate that pre-stroke SSRI exposure in ischemic stroke patients who receive thrombolytic treatment is not associated with bleeding complications, functional outcome, or mortality.

Keywords

Stroke SSRI thrombolysis outcome intracerebral hemorrhage mortality

Get full access to this article

View all access options for this article.

References

Hackam

Mrkobrada

. Selective serotonin reuptake inhibitors and brain hemorrhage: a meta-analysis. Neurology 2012; 79: 1862–1865.

McCrea

Sammon

Nazareth

Petersen

. Initiation and duration of selective serotonin reuptake inhibitor prescribing over time: UK cohort study. Br J Psychiatry 2016; 209: 421–426.

Gaduputi

Patel

Sakam

Chime

Balar

Kumar

. Serotonin reuptake inhibitors and post-gastrostomy bleeding: reevaluating the link. Ther Clin Risk Manag 2015; 11: 1283.

Mortensen

Larsson

Johnsen

Andersen

. Post stroke use of selective serotonin reuptake inhibitors and clinical outcome among patients with ischemic stroke: a nationwide propensity score-matched follow-up study. Stroke 2013; 44: 420–426.

Mortensen

Larsson

Johnsen

Andersen

. Impact of prestroke selective serotonin reuptake inhibitor treatment on stroke severity and mortality. Stroke 2014; 45: 2121–2123.

Miedema

Horvath

Uyttenboogaart

et al.

Effect of selective serotonin re-uptake inhibitors (SSRIs) on functional outcome in patients with acute ischemic stroke treated with tPA. J Neurol Sci 2010; 293: 65–67.

Siepmann

Penzlin

Kepplinger

et al.

Selective serotonin reuptake inhibitors to improve outcome in acute ischemic stroke: possible mechanisms and clinical evidence. Brain Behav 2015; 5: e00373.

Mead

Hsieh

C-F

Lee

et al.

Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery. In: Mead

(ed). Cochrane Database of Systematic Reviews, Chichester, UK: John Wiley & Sons Ltd, 2012, pp. CD009286.

Cramer

. Drugs to enhance motor recovery after stroke. Stroke 2015; 46: 2998–3005.

10.

Chollet

Tardy

Albucher

J-F

et al.

Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial. Lancet Neurol 2011; 10: 123–130.

11.

Siepmann

Kepplinger

Zerna

et al.

The effects of pretreatment versus de novo treatment with selective serotonin reuptake inhibitors on short-term outcome after acute ischemic stroke. J Stroke Cerebrovasc Dis 2015; 24: 1886–1892.

12.

Ali

Bath

PMW

Curram

et al.

The virtual international stroke trials archive. Stroke 2007; 38: 1905–1910.

13.

Hacke

. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA 1995; 274: 1017–1025.

14.

Fiorelli

Bastianello

von Kummer

et al.

Hemorrhagic transformation within 36 hours of a cerebral infarct : relationships with early clinical deterioration and 3-month outcome in the European Cooperative Acute Stroke Study I (ECASS I) cohort. Stroke 1999; 30: 2280–2284.

15.

Trouillas

von Kummer

. Classification and pathogenesis of cerebral hemorrhages after thrombolysis in ischemic stroke. Stroke 2006; 37: 556–561.

16.

Miller

Simpson

Silver

. Safety of thrombolysis in acute ischemic stroke: a review of complications, risk factors, and newer technologies. Neurohospitalist 2011; 1: 138–147.

17.

The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995; 333: 1581–1588.

18.

The NINDS t-PA Stroke Study Group. Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. Stroke 1997; 28: 2109–2118.

19.

del Zoppo

Higashida

Furlan

Pessin

Rowley

Gent

. PROACT: a phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. Stroke 1998; 29: 4–11.

20.

von Kummer

Broderick

Campbell

BCV

et al.

The Heidelberg bleeding classification. Stroke 2015; 46: 2981–2986.

21.

Hacke

Donnan

Fieschi

et al.

Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 2004; 363: 768–774.

22.

C-S

Wang

S-C

Cheng

Y-C

Gau

SS-F

. Association of cerebrovascular events with antidepressant use: a case-crossover study. Am J Psychiatry 2011; 168: 511–521.

23.

Seet

RCS

Rabinstein

. Symptomatic intracranial hemorrhage following intravenous thrombolysis for acute ischemic stroke: a critical review of case definitions. Cerebrovasc Dis 2012; 34: 106–114.

24.

Ried

Jia

Feng

et al.

Selective serotonin reuptake inhibitor treatment and depression are associated with poststroke mortality. Ann Pharmacother 2011; 45: 888–897.

25.

Pan

Sun

Okereke

Rexrode

. Depression and risk of stroke morbidity and mortality. JAMA 2011; 306: 1241.

26.

Aron

Staff

Fortunato

McCullough

. Prestroke living situation and depression contribute to initial stroke severity and stroke recovery. J Stroke Cerebrovasc Dis 2015; 24: 492–499.

27.

Lichtman

Bigger

Blumenthal

et al.

Depression and coronary heart disease: recommendations for screening, referral, and treatment. Circulation 2008; 118: 1768–1775.